+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years +
All Genders
ID04642430

Comparing Bleeding Risks of Apixaban vs Rivaroxaban for Stroke Prevention in Atrial Fibrillation Patients

Led by Ottawa Hospital Research Institute · Updated on 2026-10-01

3018

Participants Needed

8

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Atrial Fibrillation AF affects many individuals and raises the risk of stroke, which can severely impact daily functions such as speaking, walking, and self-care, and can be fatal. Blood clots forming in the heart due to AF can travel to the brain and cause strokes. Blood thinners, or anticoagulants, help reduce this risk by preventing clot formation. While warfarin has been widely used, newer direct oral anticoagulants DOACs like rivaroxaban and apixaban offer alternatives without the need for regular blood tests or dietary restrictions. However, there has been no direct comparison between these two newer drugs to assess their relative safety. This research compares the safety of apixaban taken twice daily and rivaroxaban taken once daily over 12 months in patients with non-valvular atrial fibrillation. Doses may be adjusted based on age, weight, kidney function, or creatinine clearance. Both groups receive treatment orally, with regular monitoring of kidney function at the start and annually. The trial aims to measure bleeding events and other outcomes during the treatment period. Participants will be followed for one year, with researchers monitoring bleeding complications, stroke or transient ischemic attack events, medication adherence, mortality, and cost-effectiveness. These assessments include clinical evaluations and tracking of any significant bleeding episodes. This trial will help inform treatment choices by comparing the safety profiles of these two anticoagulants for stroke prevention in AF.

CONDITIONS

Brief Title

COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation

Research Team

L

Lana Castellucci, MD

E

Erin Thomas

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here